Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
K9 in Diabetic Macular Edema
NCT06781255Phase 1Terminated
- Start
- Mar 2025
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of kamlanoflast in diabetic macular edema (DME). Primary endpoints: Adverse Events at 28 weeks, Central Subfield Thickness at 24 weeks and 1 more. Started Mar 2025; status: terminated.
02
Drugs
kamlanoflast
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT06781255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06781255.